Tuesday, December 27, 2016

BRIEF-Seattle Genetics announces clinical hold on several phase 1 trials of Vadastuximab Talirine

* Seattle Genetics announces clinical hold on several phase

1 trials of Vadastuximab Talirine (SGN-CD33A)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)